Conclusions
acute myeloid leukemia
ADVERSE EVENTS, DISEASE, ACUTE MYELOID LEUKEMIA
The safety outcomes were similar to those in VIALE-C without new safety signals and were well managed with standard medical care. In clinical practice, more patients with severe background disease are expected, in comparison with in VIALE-C, suggesting that it is important to carefully manage and prevent adverse events.This expanded access study showed a manageable safety profile of venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukemia who were ineligible for standard intensive induction chemotherapy.